Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: medicine

IBT: AI meets enzymes
investornutraceuticalsmedicinepress clippings
International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to makeDecember 17, 2025
100× scale-up of NCT production achieved
press releaseinvestornutraceuticalsmedicine
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of Energy
nutraceuticalsmedicinepress clippings
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of EnergyNovember 26, 2025
LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma
investornutraceuticalsmedicinepress clippings
LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and PharmaNovember 20, 2025
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideo
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
Dr. Paul Opgenorth
press releaseinvestornutraceuticalsmedicinescience
eXoZymes selected as core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturingJune 26, 2025
eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver health
press releaseinvestornutraceuticalsmedicinescience
eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver healthMay 6, 2025

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark